Skip to main content
SpringerLink
Log in

Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

The treatment of huge hepatocellular carcinoma (HCC) is still challengeable due to its deteriorative heterogeneity, for which conventional transarterial chemoembolization (TACE) is proposed as an efficient therapy; however, drug-eluting beads TACE (DEB-TACE) is rarely reported in these patients. Thus, the current study aimed to explore the efficacy, prognostic factors, and safety of DEB-TACE using CalliSpheres in huge HCC patients.

Methods

Ninety-nine huge HCC patients treated by DEB-TACE using CalliSpheres were retrospectively reviewed. Treatment response, change of tumor markers, liver function indexes, progression-free survival (PFS), and adverse events were retrieved.

Results

Objective response rate (ORR) was 66.1%, 48.6%, and 23.8%, then disease control rate (DCR) was 85.5%, 67.6%, and 33.3% at month (M) 1, M3, and M6, respectively; furthermore, carcinoembryonic antigen (CEA) (p = 0.037), alpha fetoprotein (AFP) (p < 0.001), and protein induced by vitamin K absence or antagonist-II (PIVKA-II) (p < 0.001) were all declined at 1 month after DEB-TACE. The median PFS was 8.3 (95% confidence interval: 6.0–10.6) months with 1-year and 2-year PFS rates of 38.5% and 15.5%, accordingly. Moreover, elevated China liver cancer (CNLC) stage (p = 0.036, hazard ratio (HR): 1.937) and abnormal cancer antigen 199 (p = 0.019, HR: 2.465) were correlated with unfavorable PFS. Besides, liver function indexes were not deteriorated after DEB-TACE. Lastly, main adverse events included pain (20.2%), fever (17.2%), nausea (14.1%), and vomit (9.1%), which were mild and manageable.

Conclusion

DEB-TACE using CalliSpheres presents satisfying efficacy and tolerable safety in huge HCC patients, suggesting that it might be a good treatment option for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chen Z, Xie H, Hu M et al (2020) Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res 10(9):2993–3036

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Wallace MC, Preen D, Jeffrey GP, Adams LA (2015) The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol 9(6):765–779

    Article  CAS  PubMed  Google Scholar 

  3. Grandhi MS, Kim AK, Ronnekleiv-Kelly SM et al (2016) Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol 25(2):74–85

    Article  PubMed  Google Scholar 

  4. Hidaka T, Anai H, Sakaguchi H et al (2021) Efficacy of combined bland embolization and chemoembolization for huge (>/=10 cm) hepatocellular carcinoma. Minim Invasive Ther Allied Technol 30(4):221–228

    Article  PubMed  Google Scholar 

  5. Jia C, Weng J, Qin Q et al (2017) Anatomic trisegmentectomy: an alternative treatment for huge or multiple hepatocellular carcinoma of right liver. Biomed Pharmacother 88:684–688

    Article  PubMed  Google Scholar 

  6. Fang Q, Xie QS, Chen JM et al (2019) Long-term outcomes after hepatectomy of huge hepatocellular carcinoma: a single-center experience in China. Hepatobiliary Pancreat Dis Int 18(6):532–537

    Article  PubMed  Google Scholar 

  7. Ariizumi S, Kotera Y, Takahashi Y et al (2013) Impact of hepatectomy for huge solitary hepatocellular carcinoma. J Surg Oncol 107(4):408–413

    Article  PubMed  Google Scholar 

  8. Xue T, Le F, Chen R et al (2015) Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study. Med Oncol 32(3):64

    Article  PubMed  Google Scholar 

  9. Huang J, Hernandez-Alejandro R, Croome KP et al (2012) Hepatic resection for huge (>15 cm) multinodular HCC with macrovascular invasion. J Surg Res 178(2):743–750

    Article  PubMed  Google Scholar 

  10. Tsurusaki M, Murakami T (2015) Surgical and locoregional therapy of HCC: TACE. Liver Cancer 4(3):165–175

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Li C, Wang MD, Lu L et al (2019) Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (>/= 10 cm): a multicenter propensity matching analysis. Hepatol Int 13(6):736–747

    Article  PubMed  Google Scholar 

  12. Wei CY, Chen PC, Chau GY et al (2020) Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Ann Transl Med 8(5):238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zhu SL, Zhong JH, Ke Y et al (2015) Efficacy of hepatic resection vs transarterial chemoembolization for solitary huge hepatocellular carcinoma. World J Gastroenterol 21(32):9630–9637

    Article  PubMed  PubMed Central  Google Scholar 

  14. Melchiorre F, Patella F, Pescatori L et al (2018) DEB-TACE: a standard review. Future Oncol 14(28):2969–2984

    Article  CAS  PubMed  Google Scholar 

  15. Reyes DK, Vossen JA, Kamel IR et al (2009) Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 15(6):526–532

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52

    Article  PubMed  Google Scholar 

  17. Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111(2):255–264

  18. Wu B, Zhou J, Ling G et al (2018) CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol 16(1):69

    Article  PubMed  PubMed Central  Google Scholar 

  19. Zhou TY, Zhou GH, Zhang YL et al (2020) Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma. J Cancer 11(15):4534–4541

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bi Y, Shi X, Yi M et al (2021) Pirarubicin-loaded CalliSpheres(R) drug-eluting beads for the treatment of patients with stage III-IV lung cancer. Acta Radiol 284185121994298

  21. Liang B, Xiang H, Ma C et al (2020) Comparison of chemoembolization with CalliSpheres((R)) microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study. Cancer Manag Res 12:941–956

    Article  PubMed  PubMed Central  Google Scholar 

  22. Ma Y, Zhao C, Zhao H et al (2019) Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres((R)) microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients. Am J Transl Res 11(12):7456–7470

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Zhao C, Ma S (2019) Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres(R) microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma. J BUON 24(3):1150–1166

    PubMed  Google Scholar 

  24. Duan XH, Ju SG, Han XW et al (2020) Arsenic trioxide-eluting CalliSpheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients. Eur Rev Med Pharmacol Sci 24(3):1468–1480

    PubMed  Google Scholar 

  25. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60

    Article  CAS  PubMed  Google Scholar 

  26. Dong J, Zhai X, Chen Z et al (2016) Treatment of huge hepatocellular carcinoma using cinobufacini injection in transarterial chemoembolization: a retrospective study. Evid Based Complement Alternat Med 2016:2754542

    Article  PubMed  PubMed Central  Google Scholar 

  27. Wu Y, Qi H, Cao F et al (2020) TACE-sorafenib with thermal ablation has survival benefits in patients with huge unresectable hepatocellular carcinoma. Front Pharmacol 11:1130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Vogl TJ, Gruber-Rouh T (2019) HCC: transarterial therapies-what the interventional radiologist can offer. Dig Dis Sci 64(4):959–967

    Article  CAS  PubMed  Google Scholar 

  29. Lencioni R, Llovet JM, Han G et al (2016) Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 64(5):1090–1098

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Qiaokou District, Hubei, 430030, Wuhan, China

    Zi Wang, Ketao Mu, Yinzhang Lv, Lingyun Zhao, Basen Li, Yonghong Hao & Nan Wang

Authors
  1. Zi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ketao Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yinzhang Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lingyun Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Basen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yonghong Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee. The written informed consents were acquired from the patients or their relatives.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (TIF 700 KB)

Supplementary file2 (TIF 1653 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Z., Mu, K., Lv, Y. et al. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients. Ir J Med Sci 191, 2493–2499 (2022). https://doi.org/10.1007/s11845-021-02851-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-021-02851-5

Keywords

Search

Navigation